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article under the CC BY-NC-ND licenseAbstract Objective: In prostate specimens, chronic inflammatory infiltrate (CII) type IV has
been detected, but its association with prostate cancer (PCa) is controversial. The aim of
the present study is to investigate on associations of CII with PCa detection in patients under-
going prostate first biopsy set.
Methods: Ultrasound transrectal-guided biopsies by the transperineal approach were retro-
spectively evaluated in 441 consecutive patients. The study excluded patients who were in
active surveillance, prostate specific antigen (PSA) 30 ng/mL, re-biopsies, incidental PCa af-
ter transurethral resection of the prostate (TURP), less than 14 cores or metastatic. Analysis of
population and subpopulations (with or without PCa) was performed by statistical methods
which included ManneWhitney (U test), KruskaleWallis test, Chi-squared statistic, logistic
regression. Multivariate logistic regression models predicting mean probability of PCa detec-
tion were established.
Results: PCa detection rate was 46.03%. Age, PSA, prostate volume (PV), prostate intraepithe-
lial neoplasia (PIN) and CII were the significant independent predictors of PCa detection. PV
(OR Z 0.934) and CII (OR Z 0.192) were both negative independent predictors. CII was a sig-
nificant negative independent predictor in multivariate logistic regression models predicting
the mean probability of PCa detection by age, PSA and PV. The inverse association of CII with
PCa does not necessary mean protection because of PSA confounding.com (A.B. Porcaro).
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Prostate chronic inflammation type IV and prostate cancer risk in patients 225Conclusion: In a population of patients undergoing prostate first biopsy set, CII was a strong
negative independent predictor of PCa detection. CII type IV should be considered as an
adjunctive parameter in re-biopsy or active surveillance protocols.
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creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The concept of zonal anatomy is used to indicate origin and
location of growing processes within the prostate [1]. The
two major diseases affecting the human prostate are
benign prostate hyperplasia (BPH) and prostate cancer
(PCa), and the former predominantly develops within the
transition zone while the latter in the peripheral part of the
gland.
The prostate gland may also undergo chronic inflam-
matory processes. The prostate is considered an immuno-
competent organ and its environment is populated by
inflammatory cells including T and B lymphocytes, macro-
phages and mast cells [2,3]. The histology of proliferative
inflammatory atrophy (PIA), which appears as simple atro-
phy or postatrophic hyperplasia, includes proliferative
glandular epithelium and associates with inflammation [3].
It has been suggested that infiltrates and mediators of
chronic inflammation might be involved in PCa carcino-
genesis [4e12]. Basic science has shown that chronic
inflammation plays an important role in human carcino-
genesis [2,3]; indeed, development and progression of
cancer might be related to reactive oxygen and nitrogen
species developing in tissue microenvironment after
related damage and regeneration [13e21]. Experimental
and epidemiologic studies show that estrogens might also
have an independent role in chronic inflammation and PCa
carcinogenesis [22e26]. There are studies showing that
chronic inflammation is the link between BPH and PCa
[27,28]. Because of the association of chronic inflammation
with oxidative stress which is mediated by the cyclo-oxy-
genase (COX) gene pathway, it has been proposed that
aspirin, which is a nonsteroidal anti-inflammatory drug,
might prevent PCa carcinogenesis by inhibiting COXs
[29e31]. However, the inflammatory infiltrate includes
cells of both the innate (e.g., monocytes and macrophages)
and adaptive (B and T lymphocytes) immune system which
is currently used for PCa immunotherapy strategies [5,32].
Clinically, the prostatitis syndromes have been classified
in four categories by the National Institutes of Health (NIH)
[33]. The last category is named type IV and is diagnosed in
patients who have no history of genitourinary tract pain
complaints, but undergo prostate biopsy for evaluation of
possible PCa because of increased serum prostate specific
antigen (PSA) level, abnormal digital rectal exam (DRE) or
both. The presence of chronic inflammatory infiltrate (CII)
has been detected in prostate specimens and might be
involved in the growing processes involving both PCa and
BPH [34e37]. However, the nature of the association of
CII with PCa is a matter of controversy and still holds
unsettled.The aim of the present study was to investigate on as-
sociations, if any, of CII with PCa detection in a population
of patients who were referred to our institution for a first
set biopsy because of suspected PCa.
2. Materials and methods
We retrospectively reviewed the records of 1260 patients
who underwent transrectal ultrasound biopsy (TRUSB) at
our institution from September 2010 to September 2014.
Excluding criteria were as follows: (i) prostate re-biopsy,
(ii) patients in active surveillance, (iii) PSA  30 mg/dL, (iv)
metastatic patients, (v) number of biopsy cores less than
14, (vi) incidental PCa after transurethral resection of the
prostate (TURP) and (vii) painful rectal exam. After
excluding criteria, indications of TRUSB included increased
serum PSA levels, abnormal DRE with normal PSA, increased
PSA and abnormal DRE (DRE þ PSA), abnormal ultrasound
imaging of the prostate with normal PSA. Abnormal DRE
findings were as follows: diffusely hard prostate, discrete
firm area, irregular contours or prominent lobe asymmetry.
Family history of PCa (Fam PCa) and treatment with in-
hibitors of the enzyme 5-a reductase (5-ARI) were also
investigated. Age (years) and body mass index (BMI, kg/m2)
were calculated in each patient. PSA was measured by
immuno-radiometric test (normal range: 2e4 mg/dL). The
volume of the prostate (PV) was measured by TRUS before
performing biopsies. PV was determined by using the for-
mula for an ellipsoid when viewed 3-dimensionally and the
formula was transformed into volume (mL). The density of
PSA (PSAD) was also computed.
In each biopsy core, the dedicated pathologists sys-
tematically assessed the following issues: (i) length, (ii)
detection and grade of PCa according to the Gleason score
system (biopsy Gleason score: BGS), (iii) length of biopsy
core involved by PCa, (iv) prostatic intraepithelial
neoplasia (PIN), (v) chronic inflammatory infiltrate (CII),
(vi) glandular atrophy (GA) and (vii) atypical small acinar
cell proliferation (ASAP). Chronic inflammation criteria,
which have already been reported [9,10], included inflam-
matory cell infiltrate composed predominantly of lympho-
cytes associated with admixed plasma cells showing a peri-
glandular distribution pattern. Sheets of neutrophils around
and within the glands as well as aspects granulomatous
prostatitis were the histopathology criteria which excluded
a diagnosis of CII of the prostate.
According to biopsy outcome, the patient population
was clustered in subpopulations with or without PCa.
Summary statistics of population and subpopulations (with
or without PCa) were calculated, and included means (SD)
for continues variables as well as proportions (rates) for
Table 1 Statistics of the population and subpopulations of pati
Variables Population PCa
No
n Z 441 n Z
Age (year, mean  SD) 65.9  8.13 64.
BMI (kg/m2, mean  SD) 26.54  3.4 26.
PSA (ng/mL, mean  SD) 6.91  3.8 6.4
PV (mL, mean  SD) 41.1  19.5 47.
PSAD (ng/mL2, mean  SD) 0.19  0.14 0.1
FAM PCa, n (%)
No 376 (85.3) 207
Yes 65 (14.7) 31
5-ARI, n (%)
No 421 (95.5) 229
Yes 20 (4.5) 9 (2
SMK, n (%)
No 231 (52.4) 128
Yes 210 (47.6) 110
DRE, n (%)
No 420 (95.2) 224
Yes 21 (4.8) 14
GA, n (%)
No 411 (93.2) 215
Yes 30 (6.8) 23
ASAP, n (%)
No 384 (87.1) 206
Yes 57 (12.9) 32
PIN, n (%)
No 421 (95.5) 234
Yes 20 (4.5) 4 (0
CII, n (%)
No 348 (78.9) 162
Yes 93 (21.1) 76
BMI, body mass index; PCa, prostate cancer; PSA, total prostate spec
density; FAM PCa, family prostate cancer; 5-ARI, 5 a-reductase inhibito
ASAP, atypical small acinar proliferation; PIN, prostate intraepithelia
Figure 1 Prostate biopsy indications. PSA, increased serum
prostate specific antigen values; DRE, abnormal digital rectal
exam with normal PSA values; DREþPSA, both DRE and
increased PSA; IMG, abnormal prostate imaging with normal
PSA values.
226 A.B. Porcaro et al.categorical variables. The tests of ManneWhitney (U test)
and KruskaleWallis were used to compare continuous var-
iables. The Chi-squared statistic was computed to test
categorical variables. Covariates associating with PCa
detection were investigated by logistic regression. PCa
mean probability logistic regression models were computed
after assessing independent predictive variables. All tests
were two-sided, with a significance level of 0.05.
3. Results
After excluding criteria, 441 patients were available for
assessment. Prostate biopsy indications are depicted by
Fig. 1. As depicted in Fig. 1, prostate biopsies were indi-
cated because of increased serum PSA values (73.70%, 325/
441), abnormal DRE with normal PSA values (4.76%, 21/
441), both abnormal DRE and increased PSA (14.97%, 66/
441), abnormal prostate imaging with normal PSA values
(6.58%, 29/441).
As shown in Table 1, PCa was detected in 203 out of 441
patients (detection rate 46.03%). The PCa subpopulation,ents (with or without PCa) undergoing prostate biopsy.
p-Value
Yes
238 (53.97) n Z 203 (46.03)
4  7.9 67.70  7.9 <0.0001
58  3.5 26.5  3.3 0.86
 3.1 7.5  4.5 0.045
6  21.3 33.35  13.5 <0.00001
5  0.09 0.25  0.17 <0.0001
0.27
(46.9) 169 (38.3)
(7.0) 34 (7.7)
0.41
(51.9) 192 (43.5)
.0) 11 (2.5)
0.52
(29.0) 103 (23.4)
(24.9) 100 (22.7)
0.23
(50.8) 196 (44.4)
(3.2) 7 (1.6)
0.01
(48.89) 196 (44.4)
(5.2) 7 (1.6)
0.72
(47.7) 178 (40.4)
(7.3) 25 (5.7)
0.002
(53.1) 187 (42.4)
.9) 16 (3.6)
<0.0001
(36.7) 186 (42.2)
(17.2) 17 (3.9)
ific antigen; PV, prostate volume; PSAD, prostate specific antigen
r; SMK, smoking; DRE, digital rectal exam; GA, glandular atrophy;
l neoplasia; CII, chronic inflammatory infiltrate.
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significantly older with higher mean values of PSA; howev-
er, PV was significantly smaller and the corresponding
density higher. When considering the variables relating to
histopathology, CII, GA and PIN significantly were associ-
ated with PCa; moreover, the association was inverse in the
first two (CII and GA) and direct in the latter (PIN). BMI,
Fam PCa, 5-ARI, abnormal DRE and ASAP did not show any
significant association in the detection of PCa. Fig. 2 shows
the negative association of CII and PCa.
Table 2 shows that the results of univariate and multi-
variate logistic regression analysis of variables associating
with PCa detection. Age, PSA, PV, CII and PIN were the
significant independent predictive variables associating
with PCa detection in the final multivariate logistic
regression model. Moreover, the association was positive
with age (OR Z 1.076), PSA (OR Z 1.200) and PIN
(OR Z 3.875), and negative with CII (OR Z 0.192) and PV
(OR Z 0.934).
Table 3 includes six multivariate logistic regression
models which are all significant in predicting the mean
probability of PCa detection. The models are stratified by
the presence (þ) or absence () of CII which might interact
(models B, D, F) or not (models A, C, E) with the significant
continuous variables including age (model A, B), PSA
(models C, D) and PV (models E, F). Fig. 3 depicts the curves
stratified by CII of the six models which are reported in
Table 3. As shown, the probability curves of models A, C, E
have different intercepts but same slopes, while the curves
of models B, D, F have different slopes but same intercepts.
Interestingly, models A, B, C, D show that the mean prob-
ability of detecting PCa is decreased by the presence of CII
and models E, F give evidence that the inverse risk ofFigure 2 Associations of CII with PCa. CII, chronic inflam-
matory infiltrate; PCa, prostate cancer.detecting PCa by PV is even more decreased when CII is
present in the biopsy cores.
4. Discussion
In the present study, CII inversely and independently asso-
ciated with PCa detection. An inverse association between
CII and PCa has been reported by previous and recent
studies [35e44]; however, the subject has also been
approached by other investigators who failed to detect any
association at all [45e47]. Although our findings suggest that
the presence of CII decreases the probability of detecting
PCa, the negative association of CII with PCa does not
necessary mean causation. Trying to explain the reason of
such negative association of CII with PCa detection is a hard
task, however, as a theory, CII might protect from the
different steps involving PCa genesis. Indeed, it is inter-
esting to realize that recently anticancer vaccines and im-
munotherapies focus on empowering the immune system to
overcome the tumor [48e50]. Vaccine therapy or immuno-
therapies aim to stimulate the immune system and activate
an appropriate immune-mediate response against malignant
cells. The immune system consists of innate and adaptive
components. The innate immune system encompasses
phagocytic cells, natural killer cells, and cells that release
inflammatory mediators. Macrophages and dendritic cells
function as antigen presenting cells which serve as a bridge
from innate to adaptive immunity. The adaptive arm of the
immune system consists of B cells and T cells. The T cells are
the most crucial component in mediating antitumor re-
sponses induced by cancer vaccines and immunotherapies.
In the prostate microenvironment, CII might induce the
liberation of tumor related antigens which stimulate the
components of the immune system. Basic science studies
are mandatory in order to assess the nature of the inflam-
matory infiltrate and its impact on the androgenic receptors
gene in the prostate gland microenvironment. According to
the improving evidence of PCa immunotherapy efficacy and
the results of the present study, we propose, as illustrated
in Fig. 4, a schematic mechanistic diagram showing the
potential cellular exchange of signaling pathways towards
inflammation in PCa. Indeed, in early stages of PCa carci-
nogenesis, high grade PIN associates with disruption of the
basement membrane which allows the cancer cell to
migrate into the prostate microenvironment where they are
attached by inflammatory cells with delivery of tumor an-
tigens. Moreover, macrophages and dendritic cells expose
the antigens to both helper (CD4þ) and cytotoxic (CD8þ) T
lymphocytes which trigger a cytotoxic response against the
cancer cells structuring the focus of high grade PIN. As a
consequence, PCa carcinogenesis progression might be
interrupted and the risk of PCa is reduced because of the
activated immune system.
In the current study, it was shown that PV inversely
associated with PCa. This finding confirms what has already
been reported [51,52]. Moreover, our study gives evidence
how the mean probability of detecting PCa by PV may be
decreased by the presence of CII. For example (see model E
in Table 3 and Fig. 1), the probability of detecting PCa of PV
of 40 mL decreases by 60%e20% by the presence of CII
(OR Z 0.113).
Table 2 Logistic regression analysis of covariates associating with PCa detection (dependent variable) in patients who un-
derwent TRUSB (n Z 441).
Covariates B SE OR 95%CI of OR p-Value
INF SUP
Univariate logistic regression analysis
Age 0.051 0.12 1.052 1.027 1.078 <0.001
PSA 0.008 0.027 1.083 1.027 1.143 0.003
PV 0.050 0.007 0.951 0.938 0.964 <0.0001
PVD 8.421 1.223 4541.760 413.647 49867.577 <0.0001
CII 1.636 0.289 0.195 0.111 0.343 <0.0001
GA 1.097 0.443 0.334 0.140 0.795 0.013
PIN 1.011 0.568 5.005 1.646 15.224 0.005
Multivariate logistic regression analysis
Age 0.072 0.015 1.075 1.043 1.107 <0.0001
PSA 0.162 0.080 1.176 1.006 1.375 0.042
PV 0.065 0.015 0.937 0.937 0.909 <0.0001
PVD 0.452 2.538 1.571 0.011 227.302 0.859
CII 1.657 0.338 0.191 0.098 0.370 <0.00001
GA 0.788 0.516 0.455 0.165 1.1250 0.127
PIN 1.390 0.624 4.017 1.182 13.651 0.026
Final multivariate logistic regression model predicting PCa
Age 0.073 0.015 1.076 1.044 1.109 <0.0001
PSA 0.183 0.040 1.200 1.109 1.299 <0.0001
PV 0.068 0.009 0.934 0.918 0.950 <0.0001
CII 1.653 0.336 0.192 0.099 0.370 <0.0001
PIN 1.354 0.616 3.875 1.158 12.966 0.028
Intercept 3.299 0.982 0.037 0.001
B, regression coefficient; SE, standard error; OR, odds ratio; PCa, prostate cancer; PSA, prostate specific antigen; PV, prostate volume;
PIN, prostate intraepithelial neoplasia; CII, chronic inflammatory infiltrate.
Table 3 Multivariate logistic regression models predicting PCa in patients undergoing biopsy.
Model Covariates B SE OR 95%CI of OR p-Value
INF SUP
A Age 0.055 0.013 1.056 1.030 1.084 <0.0001
CII 1.693 0.295 0.184 0.103 0.328 <0.0001
Intercept 3.478 0.867 0.031 <0.0001
B Age 0.058 0.13 1.060 1.033 1.088 <0.0001
CII  age 0.025 0.04 0.975 0.967 0.984 <0.0001
Intercept 3.714 0.870 0.024 <0.0001
C PSA 0.086 0.029 1.090 1.030 1.153 0.003
CII 1.666 0.293 0.189 0.106 0.336 <0.0001
Intercept 0.447 0.220 0.639 0.042
D PSA 0.118 0.032 1.125 1.056 1.198 <0.0001
CII  PSA 0.188 0.038 0.829 0.769 0.893 <0.0001
Intercept 0.714 0.231 0.489 0.002
E PV 0.050 0.007 0.952 0.938 0.966 <0.0001
CII 1.581 0.305 0.206 0.113 0.374 <0.0001
Intercept 2.068 0.302 7.913 <0.0001
F PV 0.045 0.007 0.956 0.943 0.970 <0.0001
CII  PV 0.037 0.008 0.964 0.948 0.980 <0.0001
Intercept 1.839 0.293 6.285 <0.0001
PCa, prostate cancer; PSA, prostate specific antigen; PV, prostate volume; CII, chronic inflammatory infiltrate; B, regression coefficient;
SE, standard error; OR, odds ratio.
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Figure 3 Probability risk curves stratified by CII of the six models which are reported in Table 3. (A) CII associated with age; (B)
CII interacting with age; (C) CII associated with PSA; (D) CII interacting with PSA; (E) CII associated with PV; (F) CII interacting with
PV. CII, chronic inflammatory infiltrate; PCa, prostate cancer; PSA, total prostate specific antigen; PV, prostate volume.
Prostate chronic inflammation type IV and prostate cancer risk in patients 229PSA selection for prostate biopsy may pose a potential
bias because its increments also associate with CII [53e55].
Interestingly, our investigation gives new evidence when
dealing with this controversial subject. Indeed, as shown in
Table 3 and Fig. 1 (model C and D), for a PSA of 10 ng/mL
the mean probability of detecting PCa is decreased by 60%e
20% by CII; moreover, when PSA interacts with CII (inter-
action, model D), two completely different probability
curve risks of PCa are depicted. Indeed, the probability risk
curve elevates (positive slope) as PSA increases when CII is
absent; however, the curve declines (negative slope) when
PSA interacts with CII.
There are limits in our study. First, it was single center,
but the sample size was enough large. Second, we
measured PV by means of TRUS and not by prostatectomy
specimens; however, TRUS is widely used and is consideredand effective technique. Finally, the inverse association of
chronic inflammation with PCa might be confounded by
PSA. Indeed, PSA may elevate by both inflammation and
cancer; hence, if biopsies are performed in cases with
increased PSA, some patients will have cancer and others
CII [53e55]. Patients with inflammation may undergo biopsy
procedures more frequently than men without inflamma-
tion because of potential higher PSA levels. As a result, men
with CII will automatically be less likely to have cancer and
vice versa.
In a patient population undergoing first biopsy after
prostate assessment, CII of the prostate type IV inversely
and independently associated with a reduced risk of PCa.
In multivariate logistic mean probability models, CII was
an independent prognostic factor which lowered the risk
of PCa detection. As a consequence, CII of the prostate
Figure 4 Schematic mechanistic diagram showing the potential cellular exchange of signaling pathways towards inflammation in
prostate cancer; prostatic intraepithelial neoplasia (PIN).
230 A.B. Porcaro et al.type IV might have drawbacks for approaching and man-
aging prostate diseases. Furthermore, the role of chronic
inflammation in PCa carcinogenesis remains a controver-
sial issue which needs further clinical and basic research.
In the future, it might be interesting to include in clinical
practice other diagnostic elements such as new bio-
markers (prostate health index, phi or PCa antigen 3,
pca3) and/or multiparametric magnetic resonance imag-
ing in order to investigate the possibility of differenti-
ating the inflammatory infiltrates from high grade PIN or
PCa.
CII type IV should be considered as an adjunctive
parameter in re-biopsy or active surveillance protocols.
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